Reuters logo
BRIEF-Spectrum Pharmaceuticals announces initiation of a phase 2 trial of Poziotinib
March 30, 2017 / 11:21 AM / 8 months ago

BRIEF-Spectrum Pharmaceuticals announces initiation of a phase 2 trial of Poziotinib

March 30 (Reuters) - Spectrum Pharmaceuticals Inc

* Spectrum Pharmaceuticals announces initiation of a phase 2 trial of Poziotinib in non-small cell lung cancer patients with EGFR exon 20 insertion mutations

* Top-Line results are expected before year-end Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below